NY-JEFFERIES
22.1.2020 08:02:13 CET | Business Wire | Press release
Jefferies announced that today is the firm’s trading day to support relief efforts caused by the recent wildfires in Australia. Jefferies will offer investors the opportunity to join efforts to assist those affected by the devastation of this event by trading with Jefferies.
As previously announced, Jefferies will donate net trading commissions from today, Wednesday, January 22 for all trading in Asia Pacific securities, including equities, fixed income and FX, by the firm’s clients globally. Simultaneously, all of the firm’s global employees will also be given the opportunity to personally donate to the relief effort. Jefferies will match all client trading commissions generated today, as well as match all employee donations from across the firm. The total contribution will then be donated to relief organizations directly involved in the rescue and recovery efforts in Australia.
Rich Handler, CEO, and Brian Friedman, President, of Jefferies commented: "All of us at Jefferies, including our many colleagues in Australia, 423 across Asia Pacific and 3,813 globally, are deeply saddened and concerned about this catastrophic devastation. We hope this donation from Jefferies will help, in some small way, to ease the pain of those affected by this disaster, and we encourage our global clients and employees to join our efforts to contribute to those in need.”
Jefferies Group LLC, the largest independent full-service global investment banking firm headquartered in the U.S. focused on serving clients for over 55 years, is a leader in providing insight, expertise and execution to investors, companies and governments. Our firm provides a full range of investment banking, advisory, sales and trading, research and wealth management services across all products in the Americas, Europe and Asia. Jefferies Group LLC is a wholly owned subsidiary of Jefferies Financial Group Inc. (NYSE: JEF), a diversified financial services company.
For further information, please contact your Jefferies representative.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200121006015/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lone Star Funds Completes Acquisition of Alliance Ground International26.3.2026 13:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has completed the acquisition of Alliance Ground International (“AGI”), a leading North American airport services provider. “We are excited to partner with the AGI management team to drive the business forward,” said Donald Quintin, Chief Executive Officer of Lone Star. “The company has a superior service offering and a track record of success across its integrated operations. We see opportunities to continue to invest in the business and its people to continue to grow its capabilities and ensure it remains best-in-class in delivering for the aviation industry.” “Today marks an important next step for AGI as we move forward in partnership with Lone Star,” said Jared Azcuy, Chief Executive Officer of AGI. “Our commitment to safety, reliability, and operational service excellence remains unchanged. This partnership strengthens our ability to deliver for our airline partners and reinforces that the
Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging26.3.2026 13:30:00 CET | Press release
The Phase 1 study of RLS-1496, the first human trial of a GPX4 (selective glutathione peroxidase 4) modulator, met its primary endpoint and also demonstrated a statistically significant relationship between target engagement and clinical improvement in psoriasis and atopic dermatitis RLS-1496 is a first-in-class disease-modifying mechanism targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases of aging A second study for RLS-1496 – a Phase 1b/2a study in actinic keratosis (precancerous skin lesions) – is underway in the United States, with completion expected later this year Rubedo CEO Frederick Beddingfield, III, MD, PhD, FAAD, to moderate panel on senescence and skin at the Dermatology Innovation Forum (DIF) during the American Academy of Dermatology (AAD) annual meeting on Thursday, March 26, at 1:05 pm MT in Denver Oral presentation of data accepted at the Society for Investigative Dermatology (SID) from May 13-16, 2026, in Chicago Rubedo L
GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe26.3.2026 13:30:00 CET | Press release
COMPASS is one of the largest public‑private partnerships under the European Union’s (EU) Innovative Health Initiative (IHI). The consortium aims to advance early detection and prediction of cardiotoxicity in cancer patients and cancer survivors. The initiative will leverage AI, advanced imaging, biomarkers, and integrated care pathways. GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the IHI. Cardiovascular diseases are rising sharply among cancer patients and survivors, driven both by the increasing prevalence of pre‑existing cardiovascular conditions at diagnosis and by
M1X Global Announces Public Launch and Oversubscribed $3 Million Angel Round to Scale On-Chain Sovereign Finance26.3.2026 13:13:00 CET | Press release
M1X Global, a sovereign financial infrastructure and technology company, today announced its public launch alongside the close of an oversubscribed $3 million angel round. The funding, spanning strategic investments and grants, will support platform development and accelerate regulated institutional adoption of USDM1, the first USD-denominated, treasury collateralized sovereign debt instrument issued natively by a sovereign on public blockchain infrastructure. The $3 million in funding drew participation from leading figures across global capital markets and digital asset infrastructure, including Balaji Srinivasan, former CTO of Coinbase; Tama Churchouse, CEO of Cumberland Labs; Richard Gorelick, former Head of Market Structure at DRW; and Dan Robichaud, former CIO at Intel. Institutional participation from FJ Labs and grant funding from Stellar Development Foundation reflect strong alignment between private capital and mission-driven partners advancing blockchain-based market develop
500 Global Taps Former IFC CIO As Firm Expands Global Investment Platform26.3.2026 13:00:00 CET | Press release
Atul Mehta brings three decades of global investment leadership to board as 500 Global scales platforms aligning venture capital with national innovation and economic growth agendas. 500 Global today announced the appointment of Atul Mehta to its Board of Directors, marking an important step in the firm’s continued evolution as a global venture platform and institutional asset manager. Mehta brings more than three decades of global investment and institutional leadership experience at a time when 500 Global has observed governments, multilateral institutions, and long-term capital providers rethinking how technology-led growth is financed and scaled. He has held senior roles across private capital and development finance, including at the International Finance Corporation (IFC), where he managed multi-billion-dollar portfolios spanning technology, venture funds, infrastructure, agribusiness, healthcare, education, and financial services across emerging markets. Over his career, he has
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom